Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment |
| |
| Authors: | Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh |
| |
| Affiliation: | 1. Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary;2. Department of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary;3. Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA;4. QIMR Berghofer Medical Research Institute and The Prince Charles Hospital, Brisbane, Australia;5. Cork Adult Cystic Fibrosis Centre, Cork University Hospital, Cork, Ireland;6. Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, Debrecen, Hungary;7. Cystic Fibrosis Foundation, Bethesda, MD, USA;8. MTA-DE Vascular Biology, Thrombosis and Hemostasis Research Group, Hungarian Academy of Sciences, Debrecen, Hungary;9. Department of Biology and Medical Genetics, Charles University and Motol University Hospital, Prague, Czech Republic;10. University of Lisboa, Faculty of Sciences, BioISI-Biosystems & Integrative Sciences Institute, Lisboa, Portugal;11. Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary |
| |
| Abstract: | ![]()
BackgroundWe have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.MethodsIn this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).ResultsAfter 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV 1 ( r?=??0.5376; P?r?=??0.3285; P?1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV 1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P? ConclusionsThis study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. |
| |
| Keywords: | HE4 Cystic fibrosis Biomarker 1 BMI Sweat chloride a |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
